Zero evidence it's safe, zero evidence it's not
In the space between pharmaceutical shortage and regulatory silence, Australian compounding pharmacies quietly became something they were never meant to be — industrial suppliers of unapproved weight-loss drugs to thousands of patients. The Therapeutic Goods Administration, confronting a system that outgrew its own rules, now proposes a ban that would close a dangerous loophole while potentially stranding the very patients the loophole was serving. It is a reckoning that belongs to a larger story: what happens when human need moves faster than the institutions designed to protect it.
- Compounding pharmacies exploited a regulatory grey area to mass-produce unauthorized versions of Ozempic and Mounjaro, shipping them across Australia to thousands of customers with no safety oversight.
- The TGA has no visibility into these drugs — no efficacy testing, no adverse event reporting, no count of how many Australians are taking them — meaning harm could be spreading in silence at scale.
- The Pharmacy Guild insists legitimate compounding is being unfairly targeted, yet its own president concedes there is neither evidence of harm nor evidence of safety, exposing the core of the crisis.
- Patients who have relied on compounded drugs through months of shortage now face the prospect of abrupt cessation — and the health risks of rapid weight regain that follow.
- The TGA is consulting stakeholders toward a June 2024 decision, while doctors and patient advocates urge the government to secure regulated supply before any ban removes the only available alternative.
Australia's medicines regulator has moved to ban compounded injectable weight-loss drugs, targeting pharmacies that turned a legitimate grey area into an industrial-scale operation. The Therapeutic Goods Administration announced the proposal in early 2024, after the ABC exposed how specialist compounding pharmacies had been mass-producing unauthorized versions of Ozempic and Mounjaro — drugs approved only for type 2 diabetes but widely prescribed off-label for obesity — and shipping them across the country.
Compounding pharmacies serve a genuine purpose: creating customized medicines for patients whose needs cannot be met by commercial products. But regulations allow pharmacists to replicate existing drugs when no suitable alternative exists, and several operators exploited that language to manufacture at scale. The global shortage of semaglutide and tirzepatide — powerful GLP-1 drugs that can reduce body weight by up to 15 percent — created the demand, and compounding pharmacies filled it.
The TGA's concern is that it has no oversight of these products. Compounded medicines are not registered, not tested, and carry no requirement to report side effects. The regulator warned publicly about the risks of bulk manufacturing sterile, high-risk injectables, where a single quality failure could harm thousands simultaneously. The Pharmacy Guild's president argued the TGA was conflating responsible compounders with illegal operators — but acknowledged in the same breath that no one can confirm these drugs are safe, because no one has been checking.
For patients, the stakes are immediate. Many have been managing shortages for over a year, and compounded versions were often their only option. Stopping these medications typically leads to rapid weight regain, a cycle with its own health consequences. Patient advocates have called on the government to secure better supply of regulated brands before any ban takes effect.
The TGA expects to deliver a final decision by June 2024. A ban could eliminate an unmonitored supply chain — or leave thousands without treatment, pushing them toward online telehealth providers with little continuity of care. The regulator is attempting to contain a problem born of global demand, strained supply chains, and the distance between what patients need and what the system can deliver.
Australia's medicines regulator has drawn a line in the sand. The Therapeutic Goods Administration, which oversees all pharmaceuticals in the country, is moving to ban compounded injectable weight-loss drugs—effectively shutting down a thriving underground market that emerged from a regulatory gap. The proposal, announced in early 2024, targets pharmacies that have been mass-producing unauthorized versions of Ozempic and Mounjaro, drugs originally approved only for diabetes but increasingly prescribed off-label for weight loss. What began as a loophole has become a crisis of oversight.
Compounding pharmacies exist for a legitimate purpose. They are specialist operations licensed to create customized medications on-site when commercially available options don't meet a patient's needs—a liquid formulation for a child unable to swallow tablets, for instance. The work is legal, even necessary. But the regulations governing it contain a grey area: pharmacists may replicate existing medicines when no suitable commercial alternative exists. Several compounding pharmacies have exploited this language to manufacture Ozempic and Mounjaro at industrial scale, shipping them across Australia to thousands of customers. The ABC revealed this operation late in 2023, exposing how a system designed for individual patient care had been weaponized for bulk production.
The drugs themselves are powerful. Semaglutide and tirzepatide work by mimicking a digestive hormone called GLP-1, helping the body control blood sugar and creating a prolonged sense of fullness. Studies show they can help people shed up to 15 percent of their body weight. Approved in Australia only for type 2 diabetes, they have become globally coveted for obesity treatment, driving shortages that have rippled across continents. Australian doctors, facing desperate patients and empty shelves, began prescribing them off-label. The demand exploded. The supply collapsed. Compounding pharmacies filled the void.
The TGA's concern is straightforward but weighty: it has no control over these drugs. Compounded medications are not tested for safety, quality, or efficacy by the regulator. They do not appear on the Australian Register of Therapeutic Goods. There is no requirement to report side effects. No one knows how many people are taking these medications, or what harm might be occurring in silence. The agency is particularly alarmed by the scale—bulk manufacturing of sterile, high-risk injectable drugs means that if something goes wrong, it could affect thousands at once. The regulator stated its worry plainly: "Public health and safety concerns have emerged around the complexity and commercial scale of some compounding of extemporaneously prepared GLP-1 RAs."
Trent Twomey, president of the Pharmacy Guild, has pushed back, arguing that the TGA is conflating legitimate compounding with what he calls "cowboys" engaged in illegal bulk manufacturing. He is right that there is a difference—a pharmacist making a single dose from a single prescription for a patient whose doctor has deemed it necessary is not the same as an operation churning out hundreds of vials. Yet his own words reveal the bind: there is "zero evidence to prove there is a safety concern" with compounded weight-loss drugs, he said, but also "zero evidence to say that it is safe." No one knows because no one is looking.
Patients, meanwhile, are trapped. Many have been on these medications for over a year, battling shortages the entire time. For them, compounding was not a luxury—it was survival. When people stop taking these drugs, they regain most of the weight they lost. The cycle of rapid weight loss and regain carries its own health risks. Patients are frustrated, and their emails to journalists reflect a desperation born of abandonment by the system. Elizabeth Deveny, CEO of the Consumers Health Forum, has called on the government to secure better supply of the branded medications, acknowledging that patients with diabetes—the original approved use—have suffered most acutely.
The TGA is consulting with stakeholders and promises a final decision by June 2024. In the meantime, patients are being urged to speak with their GPs. Dr. Nicole Higgins, president of the Royal Australian College for General Practitioners, acknowledged the difficulty while warning of the risks: "The risk, though, of having an unregulated medication that's being distributed throughout Australia that is not consistent with our national rules is of huge concern." The tension is real and unresolved. A ban might protect public health by eliminating an unmonitored supply chain. It might also leave thousands of people without access to the only medication keeping them stable, forcing them back into the shortage or into the arms of online telehealth providers with no ongoing relationship to their care. The regulator is trying to solve a problem created by global demand, pharmaceutical company supply chains, and the gap between what doctors need and what the system can provide. The patients caught in the middle are waiting to see which way the scales tip.
Citas Notables
Public health and safety concerns have emerged around the complexity and commercial scale of some compounding of extemporaneously prepared GLP-1 RAs, which are sterile medicines containing high-risk active substances.— Therapeutic Goods Administration
They need to differentiate between the pharmacist making a single product off a single script because the doctor needs it, the patient needs it, and it's unavailable—and these few cowboys out there that are bulk manufacturing.— Trent Twomey, Pharmacy Guild president
La Conversación del Hearth Otra perspectiva de la historia
Why would pharmacies risk their licenses to make these drugs in bulk if the original ones are available at all?
They're not available. There's a global shortage. Ozempic and Mounjaro are approved in Australia only for diabetes, but doctors are prescribing them off-label for weight loss because patients are desperate and the demand is enormous. The compounding pharmacies saw people who couldn't get the real thing and filled the gap.
But compounding is supposed to be for individual patients, right? One prescription, one dose?
Exactly. That's the loophole. The regulations say you can replicate an existing medicine if there's no suitable commercial option. Technically true—there is no commercial weight-loss version available in Australia. So some pharmacies interpreted that as permission to manufacture at scale.
And the TGA has no idea what's in these vials?
No oversight at all. Compounded drugs aren't tested for safety or efficacy. There's no requirement to report side effects. If something goes wrong, no one would know. That's what terrifies the regulator—if a batch is contaminated or incorrectly dosed, it could harm thousands of people at once.
So the ban protects patients?
It protects them from unknown risks, yes. But it also cuts off their access to the only medication keeping them stable. Many have been on these drugs for over a year. When you stop, you regain the weight. The health consequences of that cycle are real too.
What do the pharmacies say?
The legitimate ones argue they're helping people the system abandoned. The guild president says you have to distinguish between a pharmacist filling one prescription because a patient needs it and can't get it elsewhere, versus operations that are clearly just manufacturing for profit. The TGA's proposal doesn't make that distinction.
So what happens to patients in June when the decision comes down?
That's the question everyone's asking. If it's banned, they either go without, hunt for supply on the black market, or hope the government finally secures enough of the real thing. The regulator is caught between two kinds of harm.